The estimated Net Worth of Richard A. Edlin is at least $573 Tausend dollars as of 6 September 2022. Mr. Edlin owns over 6,800 units of Eagle Pharmaceuticals Inc stock worth over $84,298 and over the last 8 years he sold EGRX stock worth over $210,732. In addition, he makes $277,886 as Independent Director at Eagle Pharmaceuticals Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mr. Edlin EGRX stock SEC Form 4 insiders trading
Richard has made over 2 trades of the Eagle Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 6,800 units of EGRX stock worth $210,732 on 6 September 2022.
The largest trade he's ever made was selling 6,800 units of Eagle Pharmaceuticals Inc stock on 6 September 2022 worth over $210,732. On average, Richard trades about 1,422 units every 222 days since 2017. As of 6 September 2022 he still owns at least 22,600 units of Eagle Pharmaceuticals Inc stock.
You can see the complete history of Mr. Edlin stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Richard Edlin biography
Richard A. Edlin serves as Independent Director of the Company. Mr. Edlin joined Greenberg Traurig, LLP in August 2000. He was named Vice Chair of the firm in September 2016 and Chair of the New York Litigation Department in January 2014. He has been a member of the firm's Executive Committee since February 2013. Mr. Edlin is a trial lawyer with broad experience in both trial and appellate courts including the U.S. Supreme Court and the Delaware Supreme Court. He has tried cases in federal and state courts across the country and has handled domestic and international arbitrations. Mr. Edlin handles a wide variety of litigation and routinely acts for companies and their management in areas such as securities, general commercial and contractual disputes, antitrust and intellectual property. He is currently handling matters for leading financial institutions arising out of the economic downturn and real estate collapse; intellectual property litigation for major electronics/consumer companies; for leading pharmaceutical companies involved in contract disputes; antitrust investigations; and for individuals involved in various commercial disputes. Mr. Edlin is a frequent lecturer on litigation strategy and is the author of Courtroom Strategies for Litigation Success. He received his B.A. degree from Tufts University, magna cum laude in history, and received his law degree from Columbia University School of Law, where he was a Harlan Fiske Stone Scholar. Our Board believes that Mr. Edlin's experience as an attorney and his demonstrated facility as a corporate and strategic advisor qualify him to serve on our Board.
What is the salary of Richard Edlin?
As the Independent Director of Eagle Pharmaceuticals Inc, the total compensation of Richard Edlin at Eagle Pharmaceuticals Inc is $277,886. There are 8 executives at Eagle Pharmaceuticals Inc getting paid more, with Scott Tarriff having the highest compensation of $7,883,700.
How old is Richard Edlin?
Richard Edlin is 59, he's been the Independent Director of Eagle Pharmaceuticals Inc since 2017. There are 4 older and 5 younger executives at Eagle Pharmaceuticals Inc. The oldest executive at Eagle Pharmaceuticals Inc is Steven Ratoff, 77, who is the Independent Director.
What's Richard Edlin's mailing address?
Richard's mailing address filed with the SEC is C/O EAGLE PHARMACEUTICALS, INC., 50 TICE BOULEVARD, SUITE 315, WOODCLIFF LAKE, NJ, 07677.
Insiders trading at Eagle Pharmaceuticals Inc
Over the last 11 years, insiders at Eagle Pharmaceuticals Inc have traded over $188,911,314 worth of Eagle Pharmaceuticals Inc stock and bought 1,029,065 units worth $16,655,732 . The most active insiders traders include Executive Capital Lphec Man..., Douglas L Braunstein und Investments Iv, L.P.Pro Que.... On average, Eagle Pharmaceuticals Inc executives and independent directors trade stock every 43 days with the average trade being worth of $193,721. The most recent stock trade was executed by Scott Tarriff on 1 November 2023, trading 21,619 units of EGRX stock currently worth $299,207.
What does Eagle Pharmaceuticals Inc's logo look like?
Complete history of Mr. Edlin stock trades at Eagle Pharmaceuticals Inc
Eagle Pharmaceuticals Inc executives and stock owners
Eagle Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Scott Tarriff,
Chief Executive Officer, Director -
David Pernock,
President, Chief Operating Officer -
David M. Pernock,
Exec. VP of Operations -
Brian Joseph Cahill,
Chief Financial Officer -
Michael Graves,
Independent Chairman of the Board -
Steven Ratoff,
Independent Director -
Robert Glenning,
Independent Director -
Jennifer Simpson,
Independent Director -
Richard Edlin,
Independent Director -
Lisa Wilson,
IR Contact Officer -
Brian Cahill,
Chief Financial Officer, Principal Accounting Officer, Principal Financial Officer -
Debra M. Hussain,
Sr. VP & Head of Commercial -
Reiner Nowak,
Exec. -
Dr. Gaozhong Zhu Ph.D.,
Sr. VP of Pharmaceutical Devel. -
Dr. Valentin R. Curt M.D.,
Sr. VP of Clinical Drug Devel. -
John Kimmet,
Exec. VP of Marketing Oncology & Acute Care -
Michael Shawn Moran,
Exec. VP, Chief Commercial Officer & Principal Operating Officer -
Daniel O'Connor,
Exec. VP, Chief Strategy Officer & Head of Corp. Devel. -
Ryan Debski,
Exec. VP, Gen. Counsel & Chief Compliance Officer -
Steven L. Krill,
Chief Scientific Officer -
Pete A. Meyers,
Chief Financial Officer -
David E Riggs,
Chief Financial Officer -
Investments Iv, L.P.Pro Que...,
-
Sander A Flaum,
Director -
Douglas L Braunstein,
Director -
Executive Capital Lphec Man...,
-
Alain Schreiber,
Director -
Jay Moorin,
Director -
Management Llc Pro Quest In...,
-
Financial Llc Pro Quest Inv...,
-
Paul Bruinenberg,
Chief Medical Officer -
Associates Iv Llc Pro Quest...,
-
Judith Ng Cashin,
Chief Medical Officer -
Luciana Borio,
Director -
Michael Shawn Moran,
EVP, Chief Commercial Officer